专利检索 ipc:A61K31/506 第 1 页

1.

发明公开
BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF 审中-公开

公开(公告)号：US20240360146A1

公开(公告)日：2024-10-31

申请号：US18574511

申请日：2022-06-30

申请人： HANGZHOU HEALZEN THERAPEUTICS CO., LTD. , SHANGHAI INSTITTUTE OF MATERIA, CHINESE ACADEMY OF SCCIENCES

发明人： Xinglu ZHOU , Jia LI , Xingguo LIU , Yubo ZHOU , Miao HU , Xiaomin LUO , Jiangfeng XIE , Weijuan KAN , Mingbo SU , Yizhe WU

IPC分类号： C07D491/048 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/53 , A61K31/675 , A61K47/55 , A61P35/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/10 , C07F9/6558

CPC分类号： C07D491/048 , A61K31/4545 , A61K31/497 , A61K31/506 , A61K31/53 , A61K31/675 , A61K47/55 , A61P35/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/10 , C07F9/65583

摘要： Disclosed are a Bruton's tyrosine kinase and a mutant degrader thereof; or a stereoisomer thereof, or a stereoisomer mixture thereof or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug for treating diseases, disorders or conditions that would benefit from the degradation of the Bruton's tyrosine kinase and the mutant thereof. The compound of the present invention can degrade BTK protein, can degrade BTKC481S protein, has an anti-proliferation inhibiting effect on tumor cell strains Mino and OCI-LY10, shows good anti-tumor activity in an OCI-LY10 subcutaneous transplantation tumor model, has an inhibiting effect on B cell activation, and can be applied to B cell or plasma cell proliferative diseases and autoimmune diseases. The compound of the present invention has good oral absorption properties, and can be applied to oral treatment of human or animal B cell or plasma cell proliferative diseases and autoimmune diseases.

2.

发明公开
PYRROLYLACYLPIPERIDYLAMINE COMPOUND AND USE THEREOF 审中-公开

公开(公告)号：US20240351999A1

公开(公告)日：2024-10-24

申请号：US18569148

申请日：2022-06-10

申请人： INSTITUTE OF MATERIA MEDICA ,CHINESE ACADEMY OF MEDICAL SCIENCES

发明人： Song WU , Wenxuan ZHANG , Xintong ZHAO , Qingyun YANG , Jing FENG , Jie ZHANG , Chi ZHANG , Zunsheng HAN , Tianlei LI , Jie XIA , Kun ZHANG , Bo LIU , Huihui SHAO , Yue WANG , Yuhua HU , Xinyu LUO , Hanyilan ZHANG , Xu LIAN , Zihao ZHU

IPC分类号： C07D401/14 , A61K31/454 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , A61P31/04 , C07D413/14 , C07D417/14

CPC分类号： C07D401/14 , A61K31/454 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , A61P31/04 , C07D413/14 , C07D417/14

摘要： The present invention belongs to the technical field of antibacterial drugs, and discloses a pyrrolylacylpiperidylamine compound and use thereof. The present invention in particular relates to a pyrrolylacylpiperidylamine compound and a pharmaceutically acceptable salt thereof, and use thereof in the preparation of a medicament for resisting infections with bacteria, mycoplasma or chlamydia. The compound has a structure shown in the following general formula:

3.

发明公开
SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES 审中-公开

公开(公告)号：US20240343707A1

公开(公告)日：2024-10-17

申请号：US18631992

申请日：2024-04-10

申请人： Southern Research Institute , Oregon Health & Science University

发明人： Syed Kaleem Ahmed , Shilpa Dutta , Daniel N. Streblow , Corinne E. Augelli-Szafran , Omar Moukha-Chafiq , Ali Nakhi , Ashish Kumar Pathak

IPC分类号： C07D401/12 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/675 , A61P31/14 , C07D239/26 , C07D403/12 , C07D405/12 , C07D513/12 , C07F9/6512

CPC分类号： C07D401/12 , A61K31/505 , A61K31/506 , A61K31/55 , A61K31/675 , A61P31/14 , C07D239/26 , C07D403/12 , C07D405/12 , C07D513/12 , C07F9/6512

摘要： The present disclosure is concerned with substituted phenyl ethynyl pyrimidine compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

4.

发明公开
PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT 审中-公开

公开(公告)号：US20240343694A1

公开(公告)日：2024-10-17

申请号：US18294422

申请日：2022-08-01

申请人： KOREA RESERARCH INSTITUTE OF CHEMICAL TECHNOLOGY , INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

发明人： Kwangho LEE , Krishna Babu DUGGIRALA , Gil Don CHOI , Chong Hak CHAE , Myoung Eun JUNG , Yujin LEE , Byoung Chul CHO

IPC分类号： C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12

CPC分类号： C07D239/48 , A61K31/505 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/12

摘要： A pyrimidine derivative, a method for preparing the pyrimidine derivative, and a pharmaceutical composition comprising the pyrimidine derivative are disclosed. Also disclosed is a method for preventing or treating cancer which includes administering the pyrimidine derivative or a composition containing the pyrimidine derivative to a subject in need of cancer treatment or prevention. The pyrimidine derivative exhibits a high inhibitory ability against EGFR mutation and HER2 mutation, and thus can be effectively used in treatment of cancer in which EGFR mutation and HER2 mutation have occurred

5.

发明公开
Compositions and Methods for Treating Spinal Cord Injury and Synaptic Dysfunction 审中-公开

公开(公告)号：US20240342175A1

公开(公告)日：2024-10-17

申请号：US18617800

申请日：2024-03-27

申请人： Howard Mitz

发明人： Howard Mitz

IPC分类号： A61K31/517 , A61K31/16 , A61K31/167 , A61K31/192 , A61K31/22 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/401 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/4409 , A61K31/4439 , A61K31/472 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K31/65 , A61K35/60 , A61K36/00 , A61K38/57 , A61P25/00

CPC分类号： A61K31/517 , A61K31/16 , A61K31/167 , A61K31/192 , A61K31/22 , A61K31/352 , A61K31/381 , A61K31/40 , A61K31/401 , A61K31/428 , A61K31/437 , A61K31/44 , A61K31/4409 , A61K31/4439 , A61K31/472 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K31/65 , A61K35/60 , A61K36/00 , A61K38/57 , A61P25/00

摘要： The present invention provides methods and compositions for treating synaptic dysfunction and spinal cord injuries comprising, for example, the administration of a compound that increases the level of PZP in vivo.

6.

发明公开
CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES 审中-公开

公开(公告)号：US20240342173A1

公开(公告)日：2024-10-17

申请号：US18439926

申请日：2024-02-13

申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION , DANA-FARBER CANCER INSTITUTE, INC.

发明人： James BRADNER , Jun QI , Dennis BUCKLEY , Leonard I. ZON , Elizabeth MACARI

IPC分类号： A61K31/517 , A61K31/225 , A61K31/403 , A61K31/506 , A61K31/519 , A61K31/5415 , A61K31/55 , A61K31/7048 , A61K45/06 , A61P7/06

CPC分类号： A61K31/517 , A61K31/225 , A61K31/403 , A61K31/506 , A61K31/519 , A61K31/5415 , A61K31/55 , A61K31/7048 , A61P7/06 , A61K45/06

摘要： The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.

7.

发明授权
Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing GPR119 ligand as active ingredient 有权

公开(公告)号：US12115159B2

公开(公告)日：2024-10-15

申请号：US17275555

申请日：2019-09-11

申请人： DONG-A ST CO., LTD.

发明人： Mi-Kyung Kim , Bo Ram Lee , Hansu Park , Seung Ho Lee , Yu Na Chae

IPC分类号： A61K31/506 , A23L33/10 , A61P1/06

CPC分类号： A61K31/506 , A23L33/10 , A61P1/06

摘要： The present invention pertains to a pharmaceutical composition for preventing or treating non-alcoholic fatty liver disease, the composition containing G protein coupled receptor 119 (GPR119) ligand as an active ingredient. The pharmaceutical composition according to the present invention exhibits the excellent effects of improving lipid metabolism, reducing fat accumulation in liver tissues, and preventing histological damage caused by inflammation and fibrosis in liver tissues, and can thus be useful in preventing or treating non-alcoholic fatty liver disease.

8.

发明公开
MAP4K1 INHIBITORS 审中-公开

公开(公告)号：US20240336630A1

公开(公告)日：2024-10-10

申请号：US18578926

申请日：2022-07-14

申请人： Blueprint Medicines Corporation

发明人： Jason D. Brubaker , Michael J. Burke , Joshua T. Close , Thomas A. Dineen , Joseph L. Kim , Chandrasekhar V. Miduturu , Emanuele Perola

IPC分类号： C07D519/00 , A61K31/4375 , A61K31/497 , A61K31/506 , A61K39/395 , C07D401/12 , C07D471/04

CPC分类号： C07D519/00 , A61K31/4375 , A61K31/497 , A61K31/506 , A61K39/3955 , C07D401/12 , C07D471/04

摘要： One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.